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One of the major problems in the investigation of 
the possible immunologic basis for certain skin 
diseases is that in most cases it has not been 
possible to define the etiologic factors with any 
degree of precision. This feature is not confined to 
dermatologic research, as similar difficulties are 
found in other fields , especially in rheumatology. 
Infection with an unidentified organism, resulting 
in a wide range of clinical manifestations depend-
ing on the host's response, could underlie a number 
of dermatologic as well as rheumatologic condi-
tions, and the association of arthritis with skin 
manifestations is not an infrequent occurrence. 
Thus, the investigation of the different patterns 
of skin reaction that can occur during the varying 
patterns of host response to an organism such as 
Mycobacterium leprae may serve as a model for 
the identification of the immunologic reaction that 
might underlie those conditions where the etiologic 
agents have not yet been identified . It is of interest 
to note in passing that in infection with M. leprae, 
as with other organisms, certain patterns of host 
response may also be associated with the develop-
ment of arthritis. The relation between the varying 
clinical features of leprosy and differences in the 
host 's immunologic response holds a particular 
fascination . We can see a variety of disease pat-
terns due to increased cell-mediated immunity 
(eMI), immune complex disease , or immunologic 
deficiency. Patients may be found with a spectrum 
of immune response from high resistance with 
strong delayed hypersensitivity to low or absent 
resistance, and depending on the antigenic load 
can move backwards and forwards across the 
spectrum from one pole to the other. Reduced host 
resistance can be the product of a number of 
interacting phenomena, both constitutional and 
environmental. These include the genetic makeup 
of the individual , the state of his nutrition, and the 
presence of concurrent infection with other micro-
organisms, as well as any therapy that he may be 
receiving at the time. 
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Abbreviations: 
CY: cyclophosphamide 
CMI: cell-mediated immunity 
DNCB: dinitrochlorobenzene 
DNFB: dinitrofluorobenzene 
ENL: erythema nodosum leprosum 
FCA: Freund's complete adjuvant 
FIA: Freund's incomplete adjuvant 
OA: ovalbumin 
Perhaps the most important biologic character-
istic of M. leprae that affects its role as an etiologic 
agent in disease is that as a facultative intracellu-
lar parasite it cannot be eliminated from the body 
by humoral antibody, but as with M. tuberculosis 
the body is dependent on eMI mechanisms for the 
control of the infection. Variation in host resist-
ance to this organism is therefore related to the 
cell-mediated rather than the humoral antibody 
response. Thus , if eMI is low, host resistance will 
be low even in the face of a strong humoral 
antibody response. 
THE CLINICAL SPECTRUM OF LEPROSY 
The clinical manifestations of leprosy range from 
the typical nodular form of the disease, known as 
lepromatous leprosy, in which there is massive 
infiltration of the tissues with macrophages packed 
with colonies of mycobacteria and an apparent 
inability of the body to eliminate the organism, to 
the high-resistance form, known as tuberculoid 
leprosy, in which the microorganisms may be 
scanty or difficult to demonstrate and the skin 
lesions may resemble those of a tuberculous granu-
loma. The main site of granuloma formation in 
tuberculoid leprosy is in the peripheral nerves , and 
cutaneous lesions mayor may not be present. 
Between the two polar forms exists a wide spec-
trum of cutaneous manifestations, called border-
line leprosy. 
The internationally accepted classification of 
the clinical and histologic spectrum is that sug-
gested by Ridley and Jopling [1 ,2 ], and Ridley and 
Waters [3]. It was developed as a result of careful 
correlation of the clinical features of the disease 
with the histologic pattern observed in skin biop-
sies. The scheme is as follows: 
The Leprosy Spectrum 
TT tuberculoid polar (high resistance form) 
BT borderline tuberculoid 
BB borderline 
BL borderline lepromatous 
LI indefinite lepromatous 
LL lepromatous polar (low resistance form) 
These are, however, no more than arbitrary points 
on the spectrum. In addition, in the early stages of 
the disease a patient may not develop sufficiently 
definite characteristics to be placed accurately on 
the spectrum. Such patients are considered to have 
indeterminate leprosy and may later develop a 
more typical form of the disease or recover sponta-
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TABLE I. The spectrum of leprosy 
Characteristics 
Mycobacterium leprae in tissues 
Lymphocytic infiltration 
Lepromin test 
Antimycobacterial antibodies (% patients 
with precipitins in serum) 
Plasma cells in lymphoid tissue 
Immune complex disease (erythema nodosum 
leprosum) 
Autoantibodies in serum (%) 
Delayed hypersensitivity (%) to 
Dinitrochlorobenzene 
Hemocyanin 
neously. The only stable points on the spectrum 
are at the TT and LL poles. Thus a patient with 
BT may "downgrade" or lose resistance and move 
across the spectrum to BB or BL. Similarly, a 
patient with LI may develop a "reversal" reaction 
and move to BB or BL as he develops immunity to 
the organism. Having swung across the spectrum 
in this way, he may gain or lose resistance again 
and swing back to his original position on the 
spectrum (Tab. 1). The most unstable point is BB, 
and a patient rarely stays at this point for long, 
moving rapidly to BT or BL. 
The nature of the immunologic changes that 
occur in leprosy has been demonstrated by the 
work of Myrvang et al [4], who found that circulat-
ing lymphocytes of patients with lepromatous 
leprosy failed to be transformed in vitro by killed 
M. leprae. There was a similar failure of M. leprae 
to inhibit the migration of leukocytes from capil-
lary tubes in vitro. This defect decreases across the 
leprosy spectrum and patients at the tuberculoid 
end of the spectrum show strong reactivity in both 
these tests. Although the lymphocytes are not 
transformed by M. leprae, in many cases they can 
be induced to transform by M. tuberculosis [5]. 
THE MECHANISM OF GRANULOMA FORMATION 
IN LEPROSY 
The granuloma in the skin of lepromatous 
patients consists of large undifferentiated macro-
phages similar to those seen in experimental ani-
mals at the site of the injection of a nonantigenic 
colloidal material such as aluminum hydroxide. In 
this condition there is a conspicuous absence of 
lymphocytes and other inflammatory cells. These 
macrophages may be packed with microglobi of M. 
leprae in untreated patients. These macrophages 
change gradually into epithelioid cells as the 
spectrum is crossed through borderline to tuber-
culoid, in association with an increased infiltration 
of lymphocytes and a gradual decrease in the 
Indeterminate 
TUbe,~ Bo,Jline ;::::~atou, 
(TT) (BB) (LL) 
- or ± 
+++ 
+++ 
11-28 
± 
3-11 
90 
100 
+ or ++ 
+ 
82 
+ 
± 
75 
100 
++++ 
95 
+++ 
+++ 
30-50 
50 
100 
bacterial load . The epithelioid cell appearance is a 
measure of the activation of macrophages and is 
associated with increased ability to eliminate in-
tracellular organisms. Such activation can be pro-
duced in tissue culture by lymphokines. Similar 
macrophage activation has also been obtained in 
cultures of blood-derived macrophages, exposed to 
M. leprae in vitro, from patients with tuberculoid 
leprosy, in the presence of lymphocytes. Under 
similar conditions no activation was observed in 
cultures of macrophages from patients with lep-
romatous leprosy [5] . 
The Mitsuda lepromin test is a nodular granulo-
matous reaction that occurs between 2 and 4 weeks 
after the intradermal injection of a crude prepara-
tion of M. leprae derived from autoclaved infected 
human tissue. This reaction is positive only in the 
high resistance (TT and BT) forms of the disease. 
Its main value is to detect an inability of patients 
at the lepromatous end of the spectrum to react 
with an epithelioid cell granuloma to the injection 
of M. leprae and therefore it is a marker of a 
specific absence of eMI to this organism. The 
reaction cannot be used as an indication of contact 
with the organism, as normal individuals have 
been found to develop a positive reaction to the 
antigen. A 48-hr typical delayed-hypersensitivity 
reaction also occurs after the injection of lepromin. 
This is known as the Fernandez reaction. However, 
since most leprologists find a better correlation 
between the 2-week Mitsuda reaction and host 
resistance, the Fernandez reaction is not used as 
frequently. Many attempts have been made to 
produce a more purified lepromin either by chemi-
cal purification of the antigen or by use of the 
organism grown in another species. However, until 
recently this has only been possible by the use of 
material grown in thymectomized irradiated mice. 
Now that it has been discovered that M. leprae will 
grow in the armadillo, it is hoped that a purified 
standardized reagent will be available in a very 
short time. 
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ANIMAL MODELS OF LEPROSY 
The earliest studies on the transmission of M. 
leprae to experimental animals were in mice. 
Shepard [6] produced a limited proliferation of the 
organism in the footpads of mice. However, Rees 
and his colleagues [7] were able to achieve greater 
proliferation by injecting M. leprae into the foot-
pads of mice that had been thymectomized, given 
total-body irradiation of 900 rad and transfused 
with syngeneic bone marrow, at the age of 6 weeks. 
These mice developed nodular swelling of their 
footpads with a histologic appearance similar to 
that seem in lepromatous leprosy. Thus, a disease 
similar to lepromatous leprosy could be produced 
in mice whose immunologic activity, and espe-
cially CMI, had been depleted enough to retain 
allogeneic skin grafts. If such mice were then 
injected with syngeneic lymphocytes, they were 
found to regain CMI and develop a reaction that 
would be associated with a move across the spec-
trum to a borderline position. Histologically, there 
was evidence of increased lymphocytic infiltration 
of the infected tissue with degeneration of bacilli 
both in the skin and in Schwann cells of the 
peripheral nerves [8]. 
More recently a new animal model has been 
introduced into leprosy research [9] with the dem-
onstration that infection of the nine-banded arma-
dillo with M. leprae would result in the develop-
ment of advanced disseminated leprosy within 15 
months. Further studies indicated that the disease 
could be produced in 40 % of animals injected with 
the organism. Moreover, lepromatous tissue from 
the armadillo may contain more than 100 times 
more organisms than an equivalent amount of hu-
man lepromatous tissue. This animal can therefore 
become an important source of organisms, and 
antigens for research purposes, as well as provide 
us with a natural model for investigating the 
disease. All previous models have been in artifi-
cially immunosuppressed animals. 
REACTION STATES IN LEPROSY 
Reversal Reactions 
Reversal reactions occur in BB or in BL, often 
within the first year of the onset of therapy. Skin 
lesions flare up and become red and swollen, the 
patient becomes febrile, and there is often severe 
peripheral nerve involvement. This type of reac-
tion is associated with a movement across the 
clinical spectrum to BT, in which it would appear 
that the patient is regaining CMI as the bacterial 
load is being reduced by therapy. These changes 
can be monitored in lymph node biopsies. In the 
leprorriatous state (LL or LI) the paracortical areas 
of lymph nodes are replaced by macrophages full of 
bacilli and are depleted of lymphocytes, presum-
ably T -cells; while B-cell areas-germinal centers 
and plasma cells in the medulla-often show 
increased activity. In reversal reactions lym pho-
cytes can be seen to begin to appear in the 
paracortical areas around the postcapillary ven-
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ules, a finding suggesting the return of T-cell 
activity [10]. 
Thus, it would appear that reversal reactions are 
caused by a rapid increase in CMI against M. 
leprae in patients where CMI was originally low. 
Immunity returns in association with the decrease 
in antigenic load that follows the onset of therapy 
and with it the patient regains the capacity to 
produce hypersensitivity reactions at the site of 
residual bacterial deposition. The sites of this 
reaction are those where M. leprae accumulate-
the skin and peripheral nerves. The histologic ap-
pearance of these reactions is consistent with 
their being due to delayed hypersensitivity. 
Erythema Nodosum Leprosum (ENL) 
ENL occurs in patients at the lepromatous end 
of the spectrum where CMI against M. leprae is 
low or absent. However, these patients have high 
levels of circulating antimycobacterial antibodies 
that can be detected by precipitation [11]. 
ENL usually develops for the first time during 
the first 6 months of treatment with sulfones. The 
lesions of ENL in the skin are generally found as 
crops of erythematous nodular spots occurring in 
the normal skin between the lepromatous nodules. 
However, they may take the form of the typical 
target lesions of erythema multiforme, or they may 
be hemorrhagic or necrotic. Histologically they are 
at the site of an intense, perivascular, polymorpho-
nuclear leukocytic infiltration reminscent of that 
seen in the Arthus reaction in experimental ani-
mals. The lesion is also the site of an intense vas-
culitis. The vessels affected are generally deep in 
the dermis and often show necrotic changes. In 
some cases the lesions are more superficial and are 
associated with capillary necrosis. In biopsies of 
ENL lesions in 38 lepromatous patients, immuno-
globulins and {3 1 c/ {31 A globulin have been detected 
in areas of polymorph infiltration in 20 patients 
[12,13]. No such deposits were found in the lesions 
from 13 patients with lepromatous leprosy who had 
not had ENL. The deposits seen are granular in 
form and do not correspond to the areas of bacil-
lary infiltration. Deposits may sometimes be dem-
onstrated within the walls of blood vessels in the 
deep dermis. 
Patients with lepromatous leprosy with or with-
out ENL may develop systemic illness. This may 
be as mild as fever with a trace of proteinuria or 
more severe with arthritis or iridocyclitis. Histo-
logically the synovial membranes of involved joints 
in patients with ENL have been found to be infil-
trated with polymorphonuclear leukocytes and to 
not contain mycobacteria [14]. These observations 
suggest that as well as Arthus-like reactions in the 
skin, patients with ENL may develop illness due 
to circulating immune complexes. At the present 
time little evidence has been brought to confirm 
this suggestion. The demonstration of circulating 
complexes in diseases other thari systemic lupus 
erythematosus has been particularly elusive. So far 
there have only been isolated findings of Clq pre-
460 TURK 
cipitable material in the serum of patients with 
lepromatous leprosy [15,16]. Results using this 
technique are, however, variable and do not corre-
late with systemic disorders. Moreover, Clq can be 
precipitated by many factors in the serum other 
than specific immune complexes, including aggre-
gates of gamma globulin, biologic polyanions in-
cluding polysaccharides, and circulating immuno-
globulin-anti-immunoglobulin complexes In-
cluding cryoglobulins. 
POSSIBLE CAUSES OF DEFECT IN HOST RESISTANCE 
IN LEPROMATOUS LEPROSY 
A number of reports indicate that there may be a 
nonspecific defect in T-cell function in leproma-
tous leprosy. These possibilities range from an 
inability to be sensitized with dinitrochloroben-
zene (DNCB) [17], to a change in the proportion of 
T - and B-Iymphocytes in the peripheral blood [18, 
19], and wide replacement of the paracortical areas 
of lymph nodes by macrophages packed with M. 
leprae [20]. 
However, there are enough indications that the 
basic defect is a specific one and that nonspecific 
deficiencies in cellular immunity develop second-
ary to a primary defect in the ability to eliminate 
M. leprae alone. In the first place, there is no direct 
parallelism between failure to be sensitized to 
picryl chloride and failure to show tuberculin 
sensitivity, and there is a lower incidence of fail ure 
to be sensitized among patients who have received 
treatment for leprosy for over 18 months [21]. 
Secondly, despite an inability to sensitize 50% of 
lepromatous patients with DNCB, there was no 
difficulty in sensitizing them to develop delayed 
hypersensitivity to keyhole limpet hemocyanin 
[22]. However, the most striking evidence for the 
specificity of the primary lesion is that there is no 
increased incidence of other infections or tumors in 
leprosy, which indicates that the immunologic 
surveillance mechanisms are otherwise unim-
paired. In addition, the failure of lymphocytes to 
react in vivo by transformation also appears to be 
specific to M. leprae [5]. 
Although there are high levels of circulating 
antimycobacterial antibodies present in the serum 
of patients with lepromatous leprosy, one cannot 
explain the failure oflymphocyte responsiveness as 
being due to immunologic enhancement because 
the deficit is still demonstrable in the absence of 
autologous serum, and the serum of lepromatous 
patients does not appear to block the reactivity of 
cells from patients normally reactive to M. leprae. 
THE POSSIBLE ROLE OF SUPPRESSOR CELLS IN 
SPECIFIC IMMUNOLOGIC UNRESPONSIVENESS 
IN LEPROSY 
One of the most important features of leproma-
tous leprosy is the defect in host resistance due to a 
specific failure of T-cell function that occurs with-
out a parallel defect in B-cell function. B-cell 
function, as demonstrated by the presence of high 
levels of precipitating anti mycobacterial antibody 
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and by plasma cell proliferation and germinal 
center formation in lymph nodes, is in fact mark-
edly increased. The question then arises as to 
whether the specific T-cell unresponsiveness in 
leprosy stems from the direct suppression of poten-
tially reactive clones of T -cells. This could theoret-
ically be related to the high concentration of 
antigen which is present in the form of both live 
bacilli and soluble antigen. 
A further possibility is that in this condition the 
increased stimulation of B-cells might include a 
population of suppressor cells as well as those going 
onto conventional antibody production. It is now 
recognized that suppressor cells capable of modu-
lating aT-cell response can belong to the B-sub-
population as well as being T -cells. In our studies 
on the effect of cyclophosphamide (CY) on delayed 
hypersensitivity reactions in guinea pigs, we have 
demonstrated that suppressor B-cells are part of a 
normal immune response. The reactivity of an 
individual at any time can be considered to be the 
resultant of the balance between suppressor and 
effector elements stimulated simultaneously. 
This balance was shown best in two models of 
delayed hypersensitivity in the guinea pig. The 
first was that of contact sensitivity to dinitro-
fluorobenzene (DNFB) or oxazolone. The reactiv-
ity of guinea pigs sensitized by contact was studied 
7 days after sensitization. If they had been treated 
with CY, 300 mg/kg, 3 days before sensitization, 
which preferentially depleted B-cells [23,24], they 
developed increased reactivity compared with nor-
mal sensitized animals. This increase in reactivity 
was not due to any increase in T-cell proliferation 
in the draining lymph nodes, which was found to 
be of the same order as that in normal animals 
[25]. CY pretreatment was also found to increase 
delayed hypersensitivity of the Jones-Mote type 
in animals sensitized with ovalbumin (OA) in 
Freund's incomplete adjuvant (FIA) when skin was 
tested 7 days later [26]. In both these cases 
increased delayed hypersensitivity was associated 
with decreased or absent antibody production and 
depletion of B-Iymphocyte areas in the draining 
lymph nodes. The increased reactivity could be 
reversed in the DNFB system by transfer of spleen 
cells and the effect could be partially reproduced in 
normal animals by splenectomy 4 days after sensi-
tization. These findings suggested that in the 
normal animal, the spleen contained a significant 
population of cells that responded to antigen and, 
like those depleted by CY treatment, had a modu-
lating effect on T-cell function. In the OA/FIA 
system, the increased reactivity caused by CY 
could also be reversed by transfer of spleen or 
peritoneal exudate cells from normal donors sensi-
tized with the specific antigen in FIA or in 
Freund's complete adjuvant (FCA), indicating 
that suppressor cells are produced following any 
immunization schedule as a basic homeostatic 
feed-back mechanism [27]. In some systems, such 
as when animals are sensitized with OA in FCA, 
the relative concentration of effector elements is so 
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much greater than that of the suppressor elements, 
that removal of suppressor cells by CY does not 
produce any effect on the actively sensitized ani-
mal. That suppressor cells in these systems are 
B-cells rather than T -cells has been confirmed in 
studies on the removal of B-cells by anti-immuno-
globulin coated columns [28]. 
A number of situations now exist where a state of 
complete T-cell unresponsiveness can be shown to 
be dependent on suppressor cells and reversible by 
removing these cells by CY treatment just before 
attempted sensitization [29,30]. One of these 
situations is the model of immunologic tolerance to 
DNCB induced by the intravenous injection of 
dinitrobenzene sulfonic acid twice at a 2-weekly 
interval. This causes a failure of T -cells to prolifer-
ate when sensitization is attempted by contact 
with DNCB. However, if the animals are treated 
with CY (300 mg/kg) just before sensitization, 
suppression is reversed, T -cells proliferate, and the 
animals become sensitive. These examples of re-
versible immunologic unresponsiveness or hypo-
reactivity can be applied to the leprosy situation. 
At the lepromatous end of the spectrum, patients 
(especially those in the LI position) may develop 
reversal reactions and regain cellular immunity. It 
could be that the high antigenic load in this form of 
the disease maintains a population of suppressor 
B-cells which effectively inhibits the proliferation 
and action of effector cells that can cause the 
elimination of the infective organisms ; a high 
concentration of antimycobacterial antibody is 
present in the circulation of these patients . The 
effect of reducing the bacterial load by chemother-
apy might therefore be to reduce this population of 
B-cells and increase host resistance by restoring 
the balance in favor of the population of specific 
effector T -cells. The reaction between ant igen and 
T -cells will then result in CMI elimination of 
mycobacteria, as well as the local development of 
delayed-hypersensitivity phenomena that are asso-
ciated with reversal reactions. 
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COMPARISON BETWEEN THE IMMUNOLOGIC 
SPECTRUM OF LEPROSY AND THAT OF SYPHILIS 
A progressive relentless course of differing clini-
cal patterns is the particular feature of syphilis. 
The almost predictable evolution of clinical events 
indicates the interaction between altering degrees 
of host resistance and the superimposition of 
different forms of allergic reaction (Tab. II). Once 
the disease has passed through one phase there is 
little chance of a return to a previous position on 
the spectrum as in leprosy. It has been known for 
many years that whereas positive delayed-hyper-
sensitivity tests with treponemal antigens were 
found in late secondary and latent forms, they were 
almost universally negative in primary and second-
ary syphilis [31 ,32]. Moreover, in the primary and 
early secondary stages of the disease, dissemina-
tion of organisms and proliferation of lesions are 
accompanied by increasing amounts of circulating 
antibody. In the late secondary and latent stages, 
both lesions and detectable organisms disappear. 
Although the amount of circulating antibody rises, 
it probably makes little or no contribution to host 
resistance. 
In recent studies [33] we have noted changes in 
the responsiveness to treponemal antigens in vitro 
of lymphocytes from patients with syphilis that 
appear to parallel the spectrum of clinical manifes-
tations which mark the various stages of the 
disease. A temporary development of lymphocyte 
reactivity occurs in the primary stage, when the 
lesion is still localized. However, in the early 
secondary stage, during the phase of dissemination 
of the disease, this reactivity is lost. In contrast, 
patients with late papular form of secondary rash 
showed high levels of lymphocyte transformation. 
A striking finding was that antibiotic therapy, 
which reduces the load of infecting oragnisms, was 
followed by a marked return of the reactivity to 
levels greater than those in the primary disease. 
The reduction in lymphocyte reactivity in second-
TABLE II. The spectrum of syphilis 
B-cell function T -cell function 
Immune PHA 
Plasma Vasculitis complex Presence of trans- Luetin 
cells Antibody deposition T . pallidum forma- skin 
tion test 
1° ++ + + ++ 
2° a ++ +++ ? ++ +++ 
2° b + + ++ + + ++ 
(Microvasculitis 
granulomatosa) 
Latent ? + + + or-
3° ++ + ++ + + +++ 
Gumma 
3° ++ + ++ ++ +++ ? ± 
GPI (In CSF) 
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ary syphilis could therefore be related to the heavy 
antigenic load that exists at that time. The return 
of lymphocyte reactivity during treatment could be 
analogous to the return of CMI in the development 
of reversal reactions in patients with lepromatous 
leprosy. 
Another situation analogous to that in leprosy is 
that in secondary syphilis the patients can develop 
symptoms suggestive of immune complex disease, 
such as arthritis, iridocyclitis, and nephritis, as 
well as the secondary rash. From the secondary 
stage of the disease patients can reach a state of 
balance with the infective agent and enter the 
latent stage. Tertiary forms of the disase may 
result from a disturbance of this balance. In 
gummatous disease delayed hypersensitivity may 
be strong and antibody levels modest, whereas in 
neurosyphilis delayed hypersensitivity may be low 
and antibody levels high [31]. 
Thus, two types of spectra of clinical manifesta-
tion can be defined in chronic infections, depend-
ing as much on the response of the host as on the 
infectivity or antigenicity of the causal organism. 
Variation in host response may be the result of a 
number of different influences. These may be 
external or frequently endogenous. Two types of 
spectra may be defined: in the first type, which 
might be called a horizontal spectrum, there may 
be movement in either direction from a low resist-
ance pole to a high resistance pole. Such a spec-
trum is exemplified by the pattern found in lep-
rosy. The other, which might be called a vertical 
spectrum, is a progression from low resistance 
through high resistance and is exemplified by the 
pattern of clinical events in syphilis, where there is 
initially low resistance to the infecting organism 
followed by a higher state of resistance sufficient to 
allow a balance between immune mechanisms and 
the infecting organisms but insufficient to elimi-
nate the organism completely. The balance, how-
ever, is unstable, and in a proportion of patients it 
can be so disturbed as to result in the tertiary 
manifestations of the disease. Other examples of 
horizontal spectral diseases are among the sys-
temic mycoses, such as South American blas-
tomycosis, and such protozoal diseases as leish-
maniasis. There is also some indication of a similar 
spectrum of host response in onchocerciasis. A 
vertical spectrum similar to that in syphilis can 
also be recognized in Chagas' disease (Trypanoso-
ma cruzii). 
CONCLUSIONS 
A review has been made of the immunologic 
basis for the various clinical appearances that may 
be found during infection with M. Zeprae. This 
infection may serve as a model for the understand-
ing of the mechanisms behind the same clinical 
appearances when they occur in situations in 
which the primary etiologic agent has not yet been 
discovered. Thus, in infection with a single etio-
logic agent one may get lesions due to delayed-
hypersensitivity reactions, Arthus reactions, or 
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circulating immune complexes. Since lepromatous 
leprosy appears to involve a specific state of 
immunologic unresponsiveness for cell-mediated 
but not for humoral immunity, it might therefore 
be considered as an example of an immunodefi-
ciency disease. The balance between variations in 
the strength of host resistance and the intensity of 
allergic reactions can lead to the development of 
lesions in the skin with a number of different 
clinical appearances, each typical of a particular 
position on the clinical-immunologic spectrum. In 
addition to the variation in skin manifestations 
depending on the position of the individual on the 
spectrum, patients may develop systemic manifes-
tations of chronic disease, such as arthritis and 
uveitis. In BT leprosy, epithelioid granulomatous 
changes in the skin and lymph nodes may be 
similar to those seen in sarcoidosis. 
A similar spectrum of clinical appearances de-
pendent on the immunologic reactivity of the 
individual is found in a number of other chronic 
infectious diseases, especially syphilis and the 
chronic systemic mycoses. One might suggest, 
therefore, that the typical clinical appearance of 
particular dermatologic disorders may be the 
result of the host's reaction to a wide range of 
differing etiologic agents. In the case of an infec-
tious agent the clinical manifestation will be the 
result of the balance between the ability to develop 
an allergic reaction and resistance to the agent. 
This may, in certain circumstances, be related to a 
fail ure of T-cell dependent host resistance in the 
presence of a high level of B-cell activity producing 
antibody that can give allergic reactions but fails 
to assist in the elimination of the organism. The 
fail ure of T-cell activity may itself be directly 
related to the increased B-cell response as a result 
of an increased generation of suppressor B-cells. 
REFERENCES 
1. Ridley DS, Jopling WH: Lepr Rev 33: 119, 1962 
2. Ridley DS, Jopling WH: Int J Lepr 34:255, 1966 
3. Ridley DS, Waters MFR: Lepr Rev 40:143, 1969 
4. Myrvang B, Godal T, Ridley DS, Froland SS, Song 
YR: Clin Exp Immunol 14:541, 1973 
5. Godal T, Myklestad B, Samuel DR, Myrvang B: Clin 
Exp Immunol 9:821, 1971 
6. Shepard CC: J Exp Med 112:445, 1960 
7. Rees RJW, Waters MFR, Weddell AGM, Palmer E: 
Nature (Land) 215:599, 1967 
8. Rees RJW, Weddell AGM: Ann NY Acad Sci 
154:214, 1968 
9. Storrs EE, Walsh GP, Burchfield HP, Binford CH: 
Science 183:851, 1974 
10. Turk JL, Waters MFR: Clin Exp Immunol 8:363, 
1971 
11. Rees RJW, Chaterjee KR, Pepys J, Tee RR: Am Rev 
Resp Dis 92: 139, 1965 
12. Wemambu SNC, Turk JL, Waters MFR, Rees RJW: 
Lancet 2:933, 1969 
13. Waters MFR, Turk JL, Wemambu SNC: Int J Lepr 
39:417, 1971 
14. Karat ABA, Karat S, Job CK, Furness MA: Br Med J 
3:770, 1967 
15. Moran CJ, Ryder G, Turk JL, Waters MFR: Lancet 
2:572, 1972 
16. Rojas Espinosa 0, Mendez-Navarrette I, Estrada-
Parra S: Clin Exp Immunol 12:215, 1972 
Sept. 1976 
17. Waldorf DS, Sheagren IN, Trautman JR, Block JB: 
Lancet 2:773, 1966 
18. Dwyer JM, Bullock WE, Fields JP: N Engl J Med 
288:1036, 1973 
19. Gajl-Peczalska KM, Lim SD, Jacobson hR, Good 
RA: N Engl J Med 288:1033, 1973 
20. Turk JL, Waters MFR: Lancet 2:436, 1968 
21. Bullock WE: N Engl J Med 278:298, 1968 
22. Turk JL, Waters MFR: Lancet 2:243, 1969 
23. Turk JL, Poulter LW: Clin Exp Immunol 10:985, 
1972 
24. Poulter LW, Turk JL: Nature [New BioI] 238:17, 
1972 
25. Turk JL, Parker D, Poulter LW: Immunology 23:493, 
1972 
26. Turk JL, Parker D: Immunology 24:751, 1973 
27. Katz SI, Parker D, Sommer G, Turk JL: Nature 
(Lond) 248:612, 1974 
28 . Katz SI, Parker D, Turk JL: Nature (Lond) 251 :550, 
1974 
29. Zembala M, Asherson GL: Nature (Lond) 244:227, 
1973 
30. Polak L, Turk JL: Nature (Lond) 249:654, 1974 
31. Noguchi H: J Exp Med 14:557, 1911 
32. Michelson HE: Arch Dermatol Syphilol 25:457, 1932 
33. Friedmann PS, Turk JL: Clin Exp Immunol 21:59 , 
1975 
DISCUSSION 
Warren: Immunoregulatory phenomena are well illus-
trated by our recent studies on the mechanism of 
modulation in granulomatous hypersensitivity in chronic 
schistosomiasis . When granulomas are at their peak size 
there is strong delayed footpad swelling, MIF output to 
specific antigen by spleen cells, responsiveness of the cell 
to mitogens, and low antibody levels. In chronic schis-
tosomiasis when granulomas around new eggs are small 
there is no footpad swelling, no reactivity of spleen cells 
to both antigens and mitogens, and an exponential 
increase in antibody levels. What I am suggesting is that 
the polar movement in spectral diseases may in some and 
perhaps many cases be due to an immunoregulatory 
response. 
Turk: I agree . The resultant of all immune responses is 
a balance between suppressor elements and effector 
elements. If the suppressor elements outweigh the effec-
tor elements one gets a state of immunologic unrespon-
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siveness. Such a system occurs in immunologic tolerance 
to dinitrochlorobenzene induced by dinitrobenzene-sul-
fonic acid in the guinea pig. In this situation tolerance 
may be broken by eliminating the suppressor elements 
with cyclophosphamide. We have defined a similar 
balance in Jones-Mote reactions, which we have found to 
be delayed-hypersensitivity reactions in which effector 
T -cells are strongly modified by suppressor B-cells. 
Millikan: Thalidomide's effect in erythema nodosum 
leprosum reactions has been suggested to be 
immunoregulatory. Can you comment on its effect in 
leprosy and other hyperimmune states? 
Turk: We have tested the effect of thalidomide in a 
number of experimental models. An effect on the 
immune response has been a prolongation of skin allo-
graft survival in mice associated with a decrease in T-cell 
proliferation [Hellmann K, Duke DI, Tucker DF: Br Med 
Bull 2:687, 1965; Turk JL, Hellmann K, Duke DI: Lan-
cet 1:1134, 1966]. No effect has been observed in Arthus 
reactions . I have always wondered whether the effect of 
thalidomide in ENL is in some way to st abilize mycobac-
terial antigen and prevent it from reacting with antibody . 
Windhorst: I wonder if you would agree that a large 
percentage of people infected with syphilis do appear to 
eliminate the agent? Chronic infections have many 
analogies with cancer, both immunologically and in the 
apparent existence of individual susceptibilities . This 
raises the possibility that information from these diseases 
may be usefully extrapolated to work in cancer. Are you 
aware of any trials of immunotherapy in chronic cutane-
ous leishmaniasis or in leprosy? 
Turk: I agree that the vertical spectrum in syphilis is 
an oversimplification. Many patients with latent syphilis 
never go on to the tertiary form of the disease. However, 
the difference between leprosy and syphilis that I have 
tried to emphasize is that in the leprosy horizontal 
spectrum patients may swing from LI or BL to BT and 
back. In the syphilis vertical spectrum a patient with 
latent syphilis will not go back to the primary or 
secondary forms of the disease but rather either remain 
latent or go forward to tertiary forms of the disease. 
BCG vaccination has been used in an attempt to 
control the development ef leprosy . Initial reports from 
Uganda were hopeful but were not substantiated by 
subsequent reports from Burma and New Guinea. 
